AbilityPhama has completed the recruitment of the PanC-ASAP phase 2b clinical trial in pancreatic trial
Efficacy results of the double-blind placebo-controlled trial will be available by the end of 2024.
AbilityPharma has reached the significant milestone of successfully completing the recruitment in the phase 2b trial PanC-ASAP in pancreatic cancer.
The study is a double-blind, placebo-controlled, multicenter phase 2b study combining ABTL0812 with the chemotherapy FOLFIRINOX, as first-line in patients with metastatic pancreatic cancer.
The study has included 140 patients treated in leading centers in USA, Spain, France and Israel.
During April 2024, a committee of independent experts will conduct an interim analysis that will provide futility data to advance the study, offering valuable insights into the efficacy and safety for the patients in the trial.
AbilityPharma team is dedicated to accelerating progress in pancreatic cancer research, and it is anticipated to share unblinded efficacy results of the primary endpoint - progression free survival - by the end of this year.
The phase 2b trial in pancreatic cancer is partially funded by a grant of 2.4 million euros from the H2020 EIC (European Innovation Council) Accelerator Program of the European Commission and 1.9 million US dollars from and the US NIH R01 Orphan Drug FDA Program.